Tasquinimod
Tasquinimod
Tasquinimod (pronounced: tas-qui-ni-mod) is a small molecule drug developed for the treatment of cancer, specifically prostate cancer. It is an oral quinoline-3-carboxamide derivative that has been shown to inhibit the growth of tumor cells and the formation of new blood vessels (angiogenesis).
Etymology
The name "Tasquinimod" is derived from the chemical structure of the drug, which is a quinoline-3-carboxamide derivative. The "Tas" prefix is an abbreviation of the company that developed the drug, Active Biotech AB, based in Sweden.
Mechanism of Action
Tasquinimod works by inhibiting the growth of tumor cells and the formation of new blood vessels (angiogenesis). It does this by binding to the protein S100A9, which is involved in the regulation of inflammation and the immune response. By binding to S100A9, Tasquinimod can inhibit the growth of tumor cells and the formation of new blood vessels.
Related Terms
- Quinoline-3-carboxamide: A chemical compound that is the basis for the structure of Tasquinimod.
- S100A9: A protein that Tasquinimod binds to in order to inhibit the growth of tumor cells and the formation of new blood vessels.
- Angiogenesis: The formation of new blood vessels, which is inhibited by Tasquinimod.
- Prostate cancer: A type of cancer that Tasquinimod is being developed to treat.
External links
- Medical encyclopedia article on Tasquinimod
- Wikipedia's article - Tasquinimod
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski